



Revolutionizing GI Health – Ultrasound-Mediated Drug Delivery

Carl Schoellhammer, Ph.D. (MIT 2015)

Co-Founder and Director

cms@suonobio.com

www.suonobio.com | info@suonobio.com

Suono Bio Leadership

Founders and Leadership



Robert Langer, Sc.D.
Founder



Gio Traverso, M.D., Ph.D.
Founder



Scott Kellogg, M.S., M.B.A.,
CEO




Albert "Skip" Farinha
COO



Carl Schoellhammer, Ph.D.
Founder, CTO

Senior Advisors




Scott Snapper, M.D., Ph.D.

- Chief, Division of Gastroenterology, Children's Hospital
- Director IBD Research Brigham and Woman's Hospital



Sean Moran, M.B.A.



- CFO Corbus Pharmaceutical
- CFO InVivo Therapeutics
- CFO Sontra Medical



Tom Keagan


- Business & Market Planning
- VP NLT Spine
 - VP Zimmer Spine

Ultrasonic Platform Capabilities



Formulation-independent ultra-rapid delivery of small molecules, biologics, and nucleic acids using Suono Ultrasonic Platform


Demonstrated safety and efficacy in small and large animal models



Superior efficacy in preclinical disease models


Lead Indication: Ulcerative Colitis (UC)

- Severe inflammation of the colon
- Symptoms include: Diarrhea, occult bleeding, frequent bowel movements (20x per day)
 - U.S. prevalence: 900,000 patients
 - U.S. incidence: 34,000 new patients / year
- First line treatment includes medicated enemas using mesalamine, which is poorly absorbed
 - Treatment often fails because of insufficient absorption
 - As a result, U.S. medication spending exceeds \$10B / year




What patients need is a solution that rapidly delivers therapeutic levels of mesalamine directly into the tissue


Suono Bio's Technology can Keep Patients' Disease in Control



SoC treatment regimen leads to disease progression ultimately resulting in ostomy bag




SuonoCalm enhanced drug delivery enables superior absorption, slowing disease progression














Platform Vision – Areas of Impact

Proprietary Platform Technology: Multiple Form-Factors



Platform Vision – Areas of Impact

Platform	Modality	Candidate	Development Stage				Next Milestone	Commercial Rights
			Discovery	Preclinical	Phase 1/2	Phase 3		
Topical	 Small molecule	SUO-2002 (Mild-to-Moderate Ulcerative Colitis)					IND Submission	
	 Biologic	SUO-2003 (Severe Ulcerative Colitis)					Pre-IND Meeting	
	 Antisense	Undisclosed					-	
Tethered	 Biologic	SUO-3001 (Crohn's Disease)					Pre-IND Meeting	
	 Antisense	Undisclosed					-	
Ingestible	Multiple	Undisclosed					-	

Partnership Inquiries

- Applicable Industries:
 - Medtech
 - Pharmaceutical / chemical companies
- Types of Relationships:
 - Partnerships
 - Co-development
 - Licensing

Carl Schoellhammer, Ph.D.
cms@suonobio.com



www.suonobio.com | info@suonobio.com